Aromatase inhibitor–induced hair loss in two adolescents

Abstract

A 14-year-old boy with a strong paternal history of male pattern hair loss showed no evident hair loss on physical examination on January 28, 2019 (Figure 1A). He began treatment with anastrozole in May 2019 for idiopathic short stature. Ten months after initiation of treatment, on February 3, 2020, he developed trichoscopy-confirmed androgenetic alopecia (AGA) with a female Ludwig II pattern, primarily involving the top of the scalp (Figures 1B and 2). The patient was subsequently treated with topical minoxidil 2% daily.

Urban‐rural differences in the prevalence of female pattern hair loss among secondary school girls: A cross‐sectional study

“…23 In a major meta-analysis, only seven articles were found that discussed AGA in patients under the age of 18, and six of these were retrospective reviews or case series/reports, which described a total of 124 patients (81 male). 24 Another review included information on 531 additional pediatric patients with AGA from three unpublished studies presented as conference abstracts in a single center. 18 Limitations of the study included the narrow group of subjects and limitation of the sample to a single city.…”

“…Due to the limitations of the published studies, it is difficult to accurately assess the prevalence or incidence of AGA in the pediatric population 23 . In a major meta‐analysis, only seven articles were found that discussed AGA in patients under the age of 18, and six of these were retrospective reviews or case series/reports, which described a total of 124 patients (81 male) 24 . Another review included information on 531 additional pediatric patients with AGA from three unpublished studies presented as conference abstracts in a single center 18 .…”

Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review

“…The remaining two patients were treated for hypertension. The comorbidities in this group include two patients with eczema, one patient with Klinefelter syndrome, one patient with idiopathic short stature, and two patients with refractory hypertension secondary to underlying renal disease [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19].…”

“…Of the 373 patients, the hair disorders treated include loose anagen syndrome, androgenetic alopecia (AGA), alopecia areata, telogen effluvium, short anagen syndrome, trichotillomania, wooly hair hypotrichosis, diffuse congenital hereditary generalized hypotrichosis, kerion alopecia, premature graying, and hypotrichosis simplex-corneodesmosin (CDSN) deficiency [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. The majority of patients utilizing LDOM for hair noted improvement in hair density and a decrease in shedding [6][7][8][9][10][11][12][13][14][15][16]19].…”

“…A minority of patients experienced only stabilization of their condition [15,16], and one patient experienced a relapse [4]. We identified three studies (one cohort study and two case reports) utilizing low doses of oral minoxidil for the treatment of solely AGA [5,10,13]. In Olamiju and Craiglow [13] 2.5 mg/ day of oral minoxidil was combined with varying doses of spironolactone in six girls aged 13 to 18 years old for 5 to 13 months.…”